Madrigal: Rezdiffra sales up 50% as company posts first profitable quarter
According to TradingView, Rezdiffra sales rose 50% year on year to $431.3M in 3Q26, and $55.4M net income marked Madrigal's first profitable quarter.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Madrigal's Rezdiffra brought in $431.3M in sales during the third quarter of 2026. That is 50% higher than a year earlier.
The quarter was also the company's first profitable one, with net income reaching $55.4M. Growth rests on the expanding U.S. market for MASH treatment and on planned trials for the F4c stage.
why it matters
Turning a profit changes how investors view the stock, since the focus shifts from revenue dynamics alone to the durability of the business. Market expansion in the U.S. and plans for F4c trials shape expectations for growth ahead.
market impact
MDGL: revenue growth and first profit support the company's shares
- MDGL shares pressure up — sales growth and first net profit support demand for the stock
tags
instruments
sources
- MDGL: Rezdiffra sales rose 50% YoY as profitability began and F4c development advanced — TradingView, 3 November 2026 at 13:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗